Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Short-Term Debt: ¥0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
72 GF Score
Price ¥7.95
GF Value ¥6.76
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Short-Term Debt?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co SHSE:688505 -0.87% 72 Short-Term Debt is ¥0.0 Mil as of Jun. 2026. GuruFocus rates SHSE:688505 with a GF Score™ of 72/100 and a GF Value™ of ¥6.76 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥0.0 Mil.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Short-Term Debt Related Terms

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Short-Term Debt Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 101.00 0.00 0.00 0.00

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:688505
72GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥0.0 Mil mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) has a Short-Term Debt of ¥0.0 Mil as of Jun. 2026.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Short-Term Debt too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Short-Term Debt is ¥0.0 Mil. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Short-Term Debt compare to ZTS?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Short-Term Debt of ¥0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Short-Term Debt is ¥0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥6.76, compared to a current price of ¥7.95 — trading 17.6% above its estimated fair value. The current Short-Term Debt is ¥0.0 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505), the current Short-Term Debt is ¥0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥7.95 is trading 17.6% above its estimated GF Value™ of ¥6.76. GuruFocus considers Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:688505:

  • Short-Term Debt: ¥0.0 Mil
  • GF Value™: ¥6.76 vs. price of ¥7.95 (17.6% above fair value)
  • GF Score™: 72/100 with 1 warning sign

No single metric tells the full story. See the SHSE:688505 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
72GF Score

Get the complete analysis for SHSE:688505

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.95
Price
¥6.76
GF Value